PremiumThe FlyOutlook Therapeutics files to sell 7.07M shares of common stock for holders Outlook Therapeutics re-submits BLA to U.S. FDA for ONS-5010 Outlook Therapeutics price target lowered to $10 from $12 at Guggenheim PremiumThe FlyOutlook Therapeutics reports Q1 adjusted EPS (89c) vs. (78c) last year Outlook Therapeutics announces upcoming anticipated milestones Outlook Therapeutics Secures Funding and Board Restructures PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies Outlook Therapeutics Reports 2024 Financial Results 
